Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Many Americans have turned to Hims & Hers and other telehealth companies for copies of weight-loss drugs after struggling to ...

Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.

Canaccord raised the firm’s price target on Hims & Hers to $68 from $38 and keeps a Buy rating on the shares. Thefirm noted shares are up ...